Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 1,112,446 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $18.98, for a total transaction of $21,114,225.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total transaction of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total transaction of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total transaction of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total transaction of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total transaction of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total transaction of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.67, for a total transaction of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total transaction of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.28, for a total transaction of $172,800.00.

Shares of Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.01 during midday trading on Thursday, hitting $18.53. 197,500 shares of the stock were exchanged, compared to its average volume of 142,711. Crispr Therapeutics AG has a 1-year low of $11.63 and a 1-year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The firm had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.77) earnings per share. research analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of CRSP. Allianz Asset Management GmbH purchased a new stake in shares of Crispr Therapeutics during the third quarter worth about $2,384,000. Granahan Investment Management Inc. MA grew its holdings in shares of Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after buying an additional 89,839 shares in the last quarter. Credit Suisse AG purchased a new stake in shares of Crispr Therapeutics during the first quarter worth about $1,742,000. Adams Street Partners LLC acquired a new stake in shares of Crispr Therapeutics in the third quarter worth approximately $1,019,000. Finally, Hershey Trust Co. acquired a new stake in shares of Crispr Therapeutics in the third quarter worth approximately $768,000. Institutional investors and hedge funds own 24.55% of the company’s stock.

CRSP has been the subject of several recent research reports. BidaskClub downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Cann restated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a report on Monday, August 14th. SunTrust Banks restated a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a report on Friday, November 10th. Finally, Barclays restated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a report on Friday, September 8th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $22.38.

COPYRIGHT VIOLATION WARNING: “Crispr Therapeutics AG (CRSP) Major Shareholder Corp /De/ Celgene Sells 1,112,446 Shares” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-corp-de-celgene-sells-1112446-shares.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.